Bromitine Tablet

Bromitine mesilate is a nonhormonal, nonestrogenic agent that inhibits the secretion of prolactin in humans, with little or no effect on other pituitary hormones, except in patients with acromegaly, where it lowers elevated blood levels of growth hormone. Bromitine mesilate is a dopamine receptor agonist, which activates post-synaptic dopamine receptors.The dopaminergic neurons in the tuberoinfundibular process modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin inhibitory factor (thought to be dopamine); in the corpus striatum the dopaminergic neurons are involved in the control of motor function. Clinically, it significantly reduces plasma levels of prolactin in patients with physiologically elevated prolactin as well as in patients with hyperprolactinemia.


Hyperprolactinemia-Associated Dysfunctions: Dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Prolactin-secreting adenomasdn cases where adenectomy is elected, a course of bromocriptine mesilate therapy may be used to reduce the tumor mass prior to surgery.

Acromegaly Parkinson's Disease: Idiopathic or postencephalitic Parkinson's disease- As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor)

Bromitine is also used to associated treatment for these conditions: Acromegaly, Parkinson's Disease (PD), Type 2 Diabetes Mellitus, Idiopathic hyperprolactinemic disorder, Neuroleptic malignant syndrome (NMS)


Trade Name Bromitine
Generic Bromocriptine
Bromocriptine Other Names Bromocriptina, Bromocriptine, Bromocriptinum, Bromocryptine, Bromoergocriptine, Bromoergocryptine
Type Tablet
Formula C32H40BrN5O5
Weight Average: 654.595
Monoisotopic: 653.221282062
Protein binding

90-96% bound to serum albumin

Therapeutic Class Antiparkinson drugs, Motility stimulants/Dopamine antagonist
Manufacturer East West Pharma
Available Country India
Last Updated: June 23, 2021 at 9:09 am


Bromocriptine Structure


Bromitine dosage

Hyperprolactinemia (Adult):

  • Initial: 1.25 mg to 2.5 mg orally daily.
  • Titration: Add 2.5 mg orally, as tolerated, to the treatment dosage every 2 to 7 days.
  • Maintenance: 2.5 mg to 15 mg orally daily.

Acromegaly (Adult):

  • Initial: 1.25 mg to 2.5 mg orally once daily, with food, at bedtime for 3 days.
  • Titration: Add 1.25 mg to 2.5 mg orally, as tolerated, to the treatment dosage every 3 to 7 days.
  • Maintenance: 20 mg to 30 mg orally daily
  • The maximum dosage should not exceed 100 mg/day.

Parkinson's Disease (Adult):

  • Initial: 1.25 mg twice daily with meals.
  • Titration: Add 2.5 mg/day, with meals, to dosage regimen every 14 to 28 days.
  • Maximum dosage: 100 mg/day.

Type 2 Diabetes (Adult):

  • Initial: 0.8 mg orally daily taken within two hours after waking in the morning with food
  • Titration: Increase by 0.8 mg weekly as tolerated
  • Maintenance: 1.6 to 4.8 mg orally daily taken within two hours after waking in the morning with food
  • The maximum dosage should not exceed 4.8 mg daily.

Hyperprolactinemia (11 to 15 years old):

  • Initial: 1.25 mg to 2.5 mg orally daily.
  • Maintenance: 2.5 mg to 10 mg orally daily.

Side Effects

Side effects in decreasing order of frequency are: nausea, headache, dizziness,fatigue, lightheadedness,vomiting .abdominal cramps,nasal congestion,constipation,diarrhea and drowsiness. A slight hypotensive effect may accompany treatment.The occurrence of adverse reactions may be lessened by temporarily reducing dosage to 0.5 mg. Abnormalities in laboratory tests may include elevations in blood urea nitrogen, SGOT, SGPT, GGPT, CPK, alkaline phosphatase and uric acid, which are usually transient and not of clinical significance.


Bromitine may interact with dopamine antagonists, butyrophenones, and certain other agents. Compounds in these categories result in a decreased efficacy of Bromitine: phenothi-azines, haloperidol, metodopramide, pimozide. Concomitant use of Bromitine with other ergot alkaloids is not recommended.

Food Interaction

  • Avoid alcohol.
  • Take with food. Food reduces irritation.

Half Life

2-8 hours

Pregnancy & Breastfeeding use

Pregnancy category B. Bromitine should not be used during lactation in postpartum women.


Uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia Bromitine mesilate should be withdrawn when pregnancy is diagnosed. Post partum period in women with a history of coronary artery disease & other severe cardiovascular conditions

Special Warning

Pediatric use: No data are available for bromocriptine use in pediatric patients under the age of 8 years

Storage Condition

Store in cool and dry place. Protect from light and moisture.

Innovators Monograph

Bromitine contains Bromocriptine see full prescribing information from innovator // generic/bromocriptine/bromocriptine-mesylate-prescribing-information" Monograph